NCT03242681

Brief Summary

The aim of this study is to compare results of endoscopy assisted nasolacrimal probing with the standard simple probing in cases with congenital nasolacrimal duct obstruction . Furthermore, investigators will identify associated anatomical anomalies. Investigators believe results of this study can be valuable in better understanding of this disease and provide a high evidence level necessary to propose a classification and management algorithm. Children with symptoms of unilateral or bilateral congenital nasolacrimal duct obstruction, no past surgical management, with one or more of the below criteria will be included:

  1. 1.Non-resolving symptoms of epiphora and/or discharge.
  2. 2.Congenital dacryocele not resolved after 1 week of lacrimal sac massage, and topical antibiotics.
  3. 3.As soon as subsidence of acute dacryocystitis. Parents will be asked about symptoms and patients will undergo lacrimal tests before and after operation in one week, one month and 3months based on a special record form. Patients will be randomly assigned to "simple probing" group or "endoscopy assisted probing" group.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
320

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 20, 2017

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

July 23, 2017

Completed
16 days until next milestone

First Posted

Study publicly available on registry

August 8, 2017

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2020

Completed
Last Updated

October 10, 2019

Status Verified

March 1, 2019

Enrollment Period

2.5 years

First QC Date

July 23, 2017

Last Update Submit

October 9, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • success rate

    absence of epiphora and discharge and negative dye disappearance test

    6 months

Secondary Outcomes (1)

  • Incidence of Treatment-Emergent Adverse Events

    6 month

Study Arms (2)

Endoscopy Assisted Probing

EXPERIMENTAL

Endoscopy Assisted Probing

Procedure: Endoscopy Assisted Probing procedure

Simple Probing

ACTIVE COMPARATOR

Simple Probing

Procedure: Endoscopy Assisted Probing procedure

Interventions

The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system

Endoscopy Assisted ProbingSimple Probing

Eligibility Criteria

Age3 Weeks - 6 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • age: 3 weeks\<Age\<6 years
  • epiphora or discharge since birth or within 8 weeks after birth

You may not qualify if:

  • Follow up less than 3 months
  • Epiphora secondary to etiologies than congenital naso-lacrimal duct obstruction such as puncta/canalicular aplasia/dysgenesis;midfacial anomalies; congenital eyelid malposition;epiblepharon; trichiasis; congenital glaucoma, tumors; blepharitis; trauma Treatment success: defined success absence of epiphora/lacrimation and discharge 6 months after intervention.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Farzad Pakdel

Tehran, Iran

Location

Study Officials

  • Farzad Pakdel, M.D.

    Farabi Hospital, Tehran University of Medical Sciences

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 23, 2017

First Posted

August 8, 2017

Study Start

July 20, 2017

Primary Completion

February 1, 2020

Study Completion

July 1, 2020

Last Updated

October 10, 2019

Record last verified: 2019-03

Locations